[go: up one dir, main page]

NO20001628L - Polymerderivater av kamptoteciner - Google Patents

Polymerderivater av kamptoteciner

Info

Publication number
NO20001628L
NO20001628L NO20001628A NO20001628A NO20001628L NO 20001628 L NO20001628 L NO 20001628L NO 20001628 A NO20001628 A NO 20001628A NO 20001628 A NO20001628 A NO 20001628A NO 20001628 L NO20001628 L NO 20001628L
Authority
NO
Norway
Prior art keywords
camptothecins
polymer derivatives
derivatives
polymer
Prior art date
Application number
NO20001628A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001628D0 (no
Inventor
Francesco Angelucci
Fabrizio Orzi
Gabriele Fachin
Valeria Caiolfa
Moreno Zamai
Antonino Suarato
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of NO20001628L publication Critical patent/NO20001628L/no
Publication of NO20001628D0 publication Critical patent/NO20001628D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
NO20001628A 1997-10-03 2000-03-29 Polymerderivater av kamptoteciner NO20001628D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721069.4A GB9721069D0 (en) 1997-10-03 1997-10-03 Polymeric derivatives of camptothecin
PCT/EP1998/006048 WO1999017804A1 (en) 1997-10-03 1998-09-22 Polymeric derivatives of camptothecins

Publications (2)

Publication Number Publication Date
NO20001628L true NO20001628L (no) 2000-03-29
NO20001628D0 NO20001628D0 (no) 2000-03-29

Family

ID=10820048

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001628A NO20001628D0 (no) 1997-10-03 2000-03-29 Polymerderivater av kamptoteciner

Country Status (28)

Country Link
US (1) US6328953B1 (xx)
EP (1) EP1019090B1 (xx)
JP (1) JP2001518521A (xx)
KR (1) KR100559068B1 (xx)
CN (1) CN1154512C (xx)
AR (1) AR013535A1 (xx)
AT (1) ATE259662T1 (xx)
AU (1) AU749321B2 (xx)
BG (1) BG64894B1 (xx)
BR (1) BR9815236A (xx)
CA (1) CA2303097A1 (xx)
DE (1) DE69821783T2 (xx)
DK (1) DK1019090T3 (xx)
EA (1) EA002030B1 (xx)
ES (1) ES2216317T3 (xx)
GB (1) GB9721069D0 (xx)
HK (1) HK1032005A1 (xx)
HU (1) HUP0003690A3 (xx)
IL (1) IL134871A (xx)
MY (1) MY116287A (xx)
NO (1) NO20001628D0 (xx)
NZ (1) NZ503879A (xx)
PL (1) PL191609B1 (xx)
PT (1) PT1019090E (xx)
TW (1) TW564178B (xx)
UA (1) UA70930C2 (xx)
WO (1) WO1999017804A1 (xx)
ZA (1) ZA988923B (xx)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
EP3406249A1 (en) 2001-02-19 2018-11-28 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor
DE60219617T2 (de) 2001-05-16 2008-01-03 Novartis Ag Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
GB0119578D0 (en) * 2001-08-10 2001-10-03 Pharmacia & Upjohn Spa Fluoro linkers
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
DK1505959T3 (da) 2002-05-16 2009-02-23 Novartis Ag Anvendelse af EDG-receptorbindingsmidler ved cancer
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP2644195A1 (en) 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
PT1675622T (pt) 2003-09-17 2017-09-19 Nektar Therapeutics Pró-fármacos de polímeros de múltiplos braços
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CN1964970B (zh) 2004-04-07 2011-08-03 诺瓦提斯公司 Iap的抑制剂
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
AR058065A1 (es) 2005-09-27 2008-01-23 Novartis Ag Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
US9006224B2 (en) 2005-11-21 2015-04-14 Novartis Ag Neuroendocrine tumor treatment
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
KR101394768B1 (ko) 2006-03-30 2014-05-21 드라이스 파마슈티컬스 아이엔씨 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
AU2007240548A1 (en) 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
US20090233905A1 (en) 2006-04-05 2009-09-17 Gregory Peter Burke Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
EP2026800A1 (en) 2006-05-09 2009-02-25 Novartis AG Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
EP2120900A2 (en) 2007-02-15 2009-11-25 Novartis AG Combination of lbh589 with other therapeutic agents for treating cancer
ES2524259T3 (es) 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
EP2628726A1 (en) 2008-03-26 2013-08-21 Novartis AG Hydroxamate-based inhibitors of deacetylases b
CN102256941A (zh) 2008-12-18 2011-11-23 诺瓦提斯公司 新的盐
JP5627597B2 (ja) 2008-12-18 2014-11-19 ノバルティス アーゲー １−［４−［１−（４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ）−エチル］−２−エチル−ベンジル］−アゼチジン−３−カルボン酸ヘミフマル酸塩
KR20110112352A (ko) 2008-12-18 2011-10-12 노파르티스 아게 1-（4-｛ｌ-［（ｅ）-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노］-에틸｝-2-에틸-벤질）-아제티딘-3-카르복실산의 신규한 다형체 형태
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
JP2012516345A (ja) 2009-01-29 2012-07-19 ノバルティス アーゲー 星細胞腫治療用置換ベンゾイミダゾール
AU2010264698C1 (en) 2009-06-26 2013-05-16 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
BR112012005400A2 (pt) 2009-09-10 2016-04-05 Irm Llc derivados do tipo éter de heteroarilas bicíclicas
PH12012500823A1 (en) 2009-11-04 2013-01-07 Novartis Ag Heterocyclic sulfonamide derivatives useful as mek inhibitors
JP2013512215A (ja) 2009-11-25 2013-04-11 ノバルティス アーゲー 二環式ヘテロアリールのベンゼン縮合６員酸素含有ヘテロ環誘導体
CA2781218A1 (en) 2009-12-08 2011-06-16 Novartis Ag Heterocyclic sulfonamide derivatives
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2011157787A1 (en) 2010-06-17 2011-12-22 Novartis Ag Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
FR2967581B1 (fr) 2010-11-19 2012-12-28 Sanofi Aventis Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
KR20140025492A (ko) 2011-04-28 2014-03-04 노파르티스 아게 17α-히드록실라제/C17,20-리아제 억제제
UY34072A (es) 2011-05-17 2013-01-03 Novartis Ag Derivados sustituidos de indol
CA2838029A1 (en) 2011-06-09 2012-12-13 Novartis Ag Heterocyclic sulfonamide derivatives
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
MX2013015001A (es) 2011-06-27 2014-03-31 Novartis Ag Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CN104080787B (zh) 2011-11-29 2016-09-14 诺华股份有限公司 吡唑并吡咯烷化合物
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
IN2014CN04174A (xx) 2011-12-22 2015-09-04 Novartis Ag
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
AU2012355613A1 (en) 2011-12-23 2014-07-17 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
CA2859867A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
EA201491260A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9278981B2 (en) 2012-05-15 2016-03-08 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
DK2861579T5 (da) 2012-05-15 2022-10-24 Novartis Ag Benzamidderivater til at hæmme aktiviteten af ABL1, ABL2 og BCR-ABL1
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
JP6427097B2 (ja) 2012-06-15 2018-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌を処置するための組成物および該組成物を製造するための方法
SG10201610869TA (en) 2012-06-26 2017-02-27 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti
JP6236083B2 (ja) 2012-08-13 2017-11-22 ノバルティス ティーアゲズントハイト アーゲー 脾臓チロシンキナーゼ（ｓｙｋ）の阻害剤としての二環式ヘテロアリールシクロアルキルジアミン誘導体
PL2903968T3 (pl) 2012-10-02 2017-05-31 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
US20150284364A1 (en) 2012-11-07 2015-10-08 Nicole Bieri Substituted indole derivatives
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
CN105263906B (zh) 2013-02-27 2018-11-23 吉利德科学公司 组蛋白脱甲基酶的抑制剂
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
JP6494633B2 (ja) 2013-09-22 2019-04-03 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されているアミノピリミジン化合物および使用方法
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
EP3122728A4 (en) 2014-03-28 2017-10-25 Calitor Sciences, LLC Substituted heteroaryl compounds and methods of use
AR099890A1 (es) 2014-03-31 2016-08-24 Epitherapeutics Aps Inhibidores de histona demetilasas
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
CA2957947A1 (en) 2014-08-27 2016-03-03 Gilead Sciences, Inc. Compounds and methods for inhibiting histone demethylases
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2019090205A1 (en) 2017-11-06 2019-05-09 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
AU2017444054B2 (en) 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
EP3740468A4 (en) 2018-01-20 2021-10-06 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
CN110577552A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-5,6-双脱氢去甲斑蝥素结合物及其应用
CN110577551A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-5,6-二溴去甲斑蝥素结合物及其应用
AU2020331879A1 (en) 2019-08-19 2022-02-24 Merus N.V. Treatment of cancer with a combination of an antibody that binds LGR5 and EGFR and a topoisomerase I inhibitor.
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof

Also Published As

Publication number Publication date
ZA988923B (en) 1999-04-12
NZ503879A (en) 2002-03-28
EA002030B1 (ru) 2001-12-24
TW564178B (en) 2003-12-01
GB9721069D0 (en) 1997-12-03
WO1999017804A1 (en) 1999-04-15
AU749321B2 (en) 2002-06-20
JP2001518521A (ja) 2001-10-16
ATE259662T1 (de) 2004-03-15
HUP0003690A3 (en) 2003-08-28
BG104355A (en) 2001-01-31
DE69821783D1 (de) 2004-03-25
AU9627398A (en) 1999-04-27
EP1019090A1 (en) 2000-07-19
PT1019090E (pt) 2004-05-31
ES2216317T3 (es) 2004-10-16
EA200000376A1 (ru) 2000-10-30
NO20001628D0 (no) 2000-03-29
CA2303097A1 (en) 1999-04-15
CN1154512C (zh) 2004-06-23
PL191609B1 (pl) 2006-06-30
KR20010015687A (ko) 2001-02-26
DE69821783T2 (de) 2004-12-30
DK1019090T3 (da) 2004-04-26
AR013535A1 (es) 2000-12-27
IL134871A (en) 2005-11-20
BG64894B1 (bg) 2006-08-31
US6328953B1 (en) 2001-12-11
IL134871A0 (en) 2001-05-20
CN1272796A (zh) 2000-11-08
EP1019090B1 (en) 2004-02-18
BR9815236A (pt) 2002-07-23
PL339574A1 (en) 2000-12-18
KR100559068B1 (ko) 2006-03-10
HK1032005A1 (en) 2001-07-06
MY116287A (en) 2003-12-31
HUP0003690A2 (hu) 2001-09-28
UA70930C2 (uk) 2004-11-15

Similar Documents

Publication Publication Date Title
NO20001628L (no) Polymerderivater av kamptoteciner
NO985694D0 (no) Fremstilling av stereoregulerte polymerer
NO20003486D0 (no) Belegg av polymerer
NO20001962D0 (no) Terapeutisk anvendelse av kinolinderivater
ATE309236T1 (de) Epothilonderivate
NO20000966L (no) Reologimodifikasjon av polymerer fremstilt ved anvendelse av metallocener
ATE289994T1 (de) Chinolin-derivate
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
DK0839136T3 (da) Benzo[g]quinolinderivater
ATE255098T1 (de) Substituierte chromanderivate
NO991560L (no) PDE IV-inhiberende 2-cyanoiminoimidazol-derivater
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
ATE255099T1 (de) Substituierte chromanderivate
PT1246817E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
DE69625733D1 (de) Verbesserte Polymerpulverstabilität
ATE281436T1 (de) Chinolin-4-yl-derivate
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
DK1030850T3 (da) Azolinderivater
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20016030L (no) Derivater av 4'-demykarosyl-8a-aza-8a-homotylosin
DE69709869D1 (de) BENZO[g]CHINOLIN DERIVATE
DE69710921D1 (de) Heterocyclische substituierte pyrrolidinamid-derivate
NO991148D0 (no) Fremstilling av 1-butyl-4-piperidinyl-metylamin
FI972381A0 (fi) Foerfarande foer framstaellning av kopolymerer foer antistatiska polymer belaeggningar

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application